A Study of LY317615 in Patients With Brain Tumors

A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00190723

Enrollment

120

Registered

2005-09-19

Start date

2002-10-31

Completion date

2006-12-31

Last updated

2007-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Glioma

Brief summary

1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.

Interventions

DRUGEnzastaurin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* You must be at least 18 years old * You must have been diagnosed with a recurrent brain tumor by MRI or CT scan * You must be able to swallow the LY317615 tablets

Exclusion criteria

* You are a woman who is pregnant or breastfeeding * In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease

Design outcomes

Primary

Measure	Time frame
To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.	—

Secondary

Measure	Time frame
To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026